Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frédéric Selle1, Florence Joly2, Laurence Gladieff3

  • 1Service d'oncologie médicale, groupe hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamennais, 75008 Paris, France.

Bulletin Du Cancer
|August 12, 2023
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026
Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

British journal of cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

Advanced ovarian cancer management now requires systematic molecular analysis for BRCA1/BRCA2 status and genomic instability. New data confirm PARP inhibitors as crucial for first-line treatment in high-grade serous ovarian cancers.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Context:

  • Management of advanced ovarian carcinomas (stages III-IV) with high-grade serous and/or endometrioid histology.
  • Evolving landscape of molecular testing and therapeutic strategies based on 2022 data.
  • Importance of identifying Homologous Recombination Deficiency (HRD) and BRCA mutations.

Purpose:

  • To provide an updated clinical perspective on ovarian carcinoma management in 2023.
  • To integrate new evidence from 2022 clinical trials into treatment algorithms.
  • To guide the systematic molecular analysis for ovarian cancer patients.

Summary:

  • Systematic molecular analysis, including BRCA1/BRCA2 status and genomic instability score, is now essential for advanced ovarian carcinomas.
Keywords:
Analyse moléculaireBRCA statusCancer ovaireGenomic instability scoreHigh grade advancedInhibiteurs de PARPMolecular analysisPARP inhibitorsScore d'instabilitéStatut BRCAgénomiquehaut grade avancéovarian cancer

Related Experiment Videos

  • Phase III trial data presented in 2022 reinforce the critical role of PARP inhibitors in first-line therapy for high-grade serous ovarian cancers.
  • A revised treatment selection algorithm incorporating recent evidence is proposed.

    • Impact:

    • Facilitates personalized treatment selection for ovarian cancer patients.
    • Optimizes the use of targeted therapies like PARP inhibitors.
    • Enhances clinical decision-making in the management of advanced ovarian carcinomas.